EC Number |
Disease |
PubMed ID |
Title of Publication |
Category |
Confidence Level |
---|
2.5.1.21 | Precursor Cell Lymphoblastic Leukemia-Lymphoma |
17392819 |
Increased resistance to a farnesyltransferase inhibitor by N-cadherin expression in Bcr/Abl-P190 lymphoblastic leukemia cells. |
causal interaction ongoing research therapeutic application unassigned |
1 4 1 0 |
2.5.1.21 | Precursor Cell Lymphoblastic Leukemia-Lymphoma |
22399601 |
Farnesyltransferase inhibitors: molecular evidence of therapeutic efficacy in acute lymphoblastic leukemia through cyclin d1 inhibition. |
causal interaction therapeutic application unassigned |
3 4 0 |
2.5.1.21 | Precursor Cell Lymphoblastic Leukemia-Lymphoma |
22934254 |
Environment-mediated drug resistance in Bcr/Abl-positive acute lymphoblastic leukemia. |
ongoing research therapeutic application unassigned |
3 4 0 |
2.5.1.21 | Primary Myelofibrosis |
12750696 |
In vitro antiproliferative activity of the farnesyltransferase inhibitor R115777 in hematopoietic progenitors from patients with myelofibrosis with myeloid metaplasia. |
causal interaction ongoing research therapeutic application unassigned |
3 2 3 0 |
2.5.1.21 | Progeria |
16126733 |
Incomplete processing of mutant lamin A in Hutchinson-Gilford progeria leads to nuclear abnormalities, which are reversed by farnesyltransferase inhibition. |
causal interaction unassigned |
2 0 |
2.5.1.21 | Progeria |
16862216 |
A farnesyltransferase inhibitor improves disease phenotypes in mice with a Hutchinson-Gilford progeria syndrome mutation. |
causal interaction ongoing research therapeutic application unassigned |
1 4 4 0 |
2.5.1.21 | Progeria |
18082640 |
Treatment with a farnesyltransferase inhibitor improves survival in mice with a Hutchinson-Gilford progeria syndrome mutation. |
causal interaction therapeutic application unassigned |
1 4 0 |
2.5.1.21 | Progeria |
18331619 |
Increased mechanosensitivity and nuclear stiffness in Hutchinson-Gilford progeria cells: effects of farnesyltransferase inhibitors. |
causal interaction therapeutic application unassigned |
1 1 0 |
2.5.1.21 | Progeria |
18838683 |
A farnesyltransferase inhibitor prevents both the onset and late progression of cardiovascular disease in a progeria mouse model. |
therapeutic application unassigned |
4 0 |
2.5.1.21 | Progeria |
20074076 |
Progeria, the nucleolus and farnesyltransferase inhibitors. |
therapeutic application unassigned |
4 0 |